Prime Medicine, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing operational updates, forward-looking program milestones, and share count data for the period.

Key Highlights

  • Share count: As of October 31, 2026, the company reported 181,921,405 shares of common stock, par value $0.00001 per share, outstanding.
  • BLA filing target: The company disclosed plans to file a Biologics License Application for PM359 in the first half of 2027, based on data from its Phase 1/2 trial for the treatment of chronic granulomatous disease (CGD).
  • Pipeline data timeline: According to the filing, initial data for both PM577a and PM647 are expected in 2027.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Exchange listing: Common stock trades on the Nasdaq Global Market under the symbol PRME (NASDAQ:PRME).
  • Going concern disclosure: The filing lists "our ability to continue as a going concern" among the subjects addressed by its forward-looking statements.

Prime Medicine Discloses Program Timelines and Financial Outlook for Q3 2026

Prime Medicine, Inc. (NASDAQ:PRME), a gene editing company headquartered at 60 First Street, Cambridge, MA 02141, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing identifies Commission file number 001-41536 and was made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company confirmed it had filed all required reports during the preceding 12 months and had submitted all required Interactive Data Files electronically.

Among the key disclosures, the filing states that the company intends to submit a Biologics License Application for PM359 to the U.S. Food and Drug Administration in the first half of 2027, drawing on data from its Phase 1/2 trial evaluating PM359 for chronic granulomatous disease. The filing also references "the continued development and advancement of PM577a and PM647, including the timing of initial data for both in 2027" as a subject of its forward-looking statements. These statements are the company's own and are expressly subject to its cautionary language regarding risks and uncertainties.

The filing also includes a going concern reference, listing "our expectations regarding the anticipated timeline of our cash runway, future financial performance and our ability to continue as a going concern" among the topics covered by forward-looking statements. The company noted that actual results could differ materially from those projected, citing factors such as macroeconomic conditions, geopolitical developments, inflationary pressures, capital market disruptions, and potential changes to or disruptions at U.S. governmental agencies.

What Was Disclosed

Prime Medicine filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, reporting 181,921,405 shares outstanding as of October 31, 2026, disclosing a planned BLA submission for PM359 in the first half of 2027, and noting anticipated 2027 data readouts for PM577a and PM647.